NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis

 
• By Ayisha Sharma

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.  

Emerging Company Profile: NMD Pharma
The Chlorine Ion Channel Is Found Exclusively In Skeletal Muscle • Source: Shutterstock

NMD Pharma has made strides with a new mechanism for the treatment of myasthenia gravis (MG) with its lead program thanks to a unique platform that harnesses ion channel function and electrophysiology of skeletal muscle.

The Danish firm was originally spun out of research conducted by CEO and co-founder Thomas Holm Pedersen on ion channels...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

More from Start-Ups & SMEs